Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Inclusion Criteria: * Histologically proven colorectal adenocarcinoma, * Primary tumor of the colon or rectum, resectable or resected at least 3 weeks before randomization or 4 weeks before the beginning of the study treatment, * Metastatic disease with synchronous or metachronous (\> 3 months after diagnosis of the primary tumor) hepatic metastasis, * Non-resectable (with respect to curative intent) hepatic metastasis at presentation. This criterion must be validated by both a surgeon and a radiologist during the RCP (Multidisciplinary cancer case presentation committee) patient's evaluation meeting (either technically non-resectable metastases (absolute contraindication): i.e. impossibility to resect all metastases in a single operation while preserving at least 30% of healthy liver tissues and/or impossibility to preserve the portal vein and hepatic artery homolateral to the liver or a portal pedicle, or due to oncological non-resectability (relative contraindication): presence of \> 5 nodules and bilateral invasion), * Hepatic metastases, without spread to other sites except in case of ≤ 3 resectable pulmonary metastases of diameter \< 2 cm, detected by thoracic scanner, * K-Ras status determined before randomization, * Measurable disease according to the RECIST V1.1 criteria, * No prior treatment of the hepatic metastases, * Previous 5FU +/- oxaliplatin-based adjuvant chemotherapy administered after colorectal tumor resection is authorized if complete more than 1 year before, * Age ≥ 18 \& ≤ 75 years * Performance status : ECOG 0 or 1, * Life expectancy ≥ 3 months, * Hemoglobin ≥ 9 g/dl, * Polynuclear neutrophiles ≥ 1500/mm3, * Platelets ≥ 100 000 mm3, * Creatinemia ≤ 135 µmol/l (1,35 mg/dl) * Total bilirubin ≤ 1.25 times the Upper Limit of Normal (ULN). * Hepatic enzymes ASAT and ALAT \< 5 x ULN, * Negative pregnancy test for women of child-bearing age, * Information given to the patient and signed informed consent, * Public Health insurance coverage. Exclusion Criteria: * Non metastatic and/or non measurable disease according to the RECIST v1.1 criteria. * Non-resectable primary tumor (e.g.: T4 tumors) or incomplete resection R2. * History of intestinal inflammatory disease. * Specific contraindication to any of the study treatments. * Patient who have previously received anti-EGFr (e.g., cetuximab) or anti-VEGF monoclonal antibody treatment (e.g., bevacizumab) or treatment with irinotecan. * History of cancer considered as not cured. * Stroke/CVA or pulmonary embolism within 6 months before inclusion. * Significant concomitant disease such as: coagulopathy, respiratory or cardiac congestive insufficiency, non-medically controlled/unstable angina pectoris, myocardial infarction within 6 months prior to study entry, arterial hypertension and uncontrolled arrhythmia, severe infections. * Clinical neuropathy, grade ≥1. * Patient already included in another therapeutic trial using an experimental molecule. * Pregnant women or women who might become pregnant during the study or lactating women. * Men or women who can procreate and who do not abide with the use of a contraceptive means. * Persons kept in detention or incapable of giving consent * Patient unwilling or unable to comply with the medical follow-up required by the trial because of geographic social or psychological reasons.